Gate Bioscience

Gate Bioscience

Private
Brisbane, CaliforniaHealthcare & Life Scienceshttps://www.gatebio.com

Last Round

Series B

Nov 13, 2025

Total Funding Raised

$125M

Momentum Score

25 /100

Company Overview

Gate Bioscience is a biotechnology company that develops small molecule drugs designed to selectively target and eliminate harmful extracellular proteins at their source within cells, thereby preventing disease emergence.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

molecular gatessmall molecule drugsprotein secretion inhibitorsdrug discovery platformprotein degradationoral small moleculesdifficult-to-drug targetsundruggable targetssecretory transloconextracellular proteinspharma partnershipsbiotech licensingneuroscience drug discoveryprotein aggregation diseasepreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gate Bioscience Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Gate Bioscience Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BNov 13, 2025
Series ANov 1, 2023

Key People

Founding team and executive leadership

Raman Talwar

Co-founder And CTO

Founding Team

Jordi Mata-Fink

Co-Founder And CEO

Founding Team

Gate Bioscience Investors

Notable investors and investment history

InvestorRounds
GVSeries A, Series B
ForbionSeries B
ARCH Venture PartnersSeries B
ARCH Venture PartnersSeries A, Series B
Versant VenturesSeries B, Series A
Andreessen Horowitz Bio + HealthSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 13, 2025

    $65M round completed.

  • Nov 13, 2025

    Vanessa Carle joins the board in connection with recent financing.

Gate Bioscience Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gate Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gate Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrisbane, California
Employee Range42
Year Founded2018
Last FundingNov 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.